Epigenomic profile and biological age
Man ages at a constant chronological rate while their biological aging rate is extremely variable. Interventions to improve, or to slow the rate of biological aging are the subject of several research. The broad spectrum of molecules and its intricate role from the biological point of view and its relation with environmental factors are being investigated. Recently, researchers have been putting its efforts to understand the epigenetic mechanisms and how it can interfere with alterations in gene expression that leads to predisposition and, or pathological outcome. Some of these investigations have shed light about how one can determine the biological age from a simple blood sample, just by detecting the epigenetic alterations on only three CpGs sites with a reasonable certainty. Also, the enzymes inhibitors that can interfere with methylation and demethylation were effective to reverse the epigenetic mechanisms. Other studies have shown how the environmental changes since from early life can affect these alterations on the epigenome. Taking all together, some biomolecular markers are already available to determine the genetic background of an individual and this information can be used to guide the lifestyle in order to prevent some future diseases development and/or improve the quality of later life.
Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Ann. Rev. Pharmacol. Toxicol. 2009; 49: 243-63. https://doi.org/10.1146/annurev-pharmtox-061008-103102.
Bergman A, Lane ME. HIDden targets of microRNAs for growth control. Trends Biochem. Sci. 2003; 28:461-63. https://doi.org/10.1016/S0968-0004(03)00175-0.
Finch JT, Lutter LC, Rhodes D, Brown RS, Rushton B, Levitt M, Klug A. Structure of nucleosome core particles of chromatin. Nature 1977; 269: 29-36. https://doi.org/10.1038/269029a0.
Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 2001; 11: 266-73. https://doi.org/10.1016/S0962-8924(01)02001-3.
Wade PA, Pruss D, Wolffe AP. Histone acetylation: chromatins in action. Trends Biochem. Sci. 1997; 22:128- 32. https://doi.org/10.1016/S0968-0004(97)01016-5.
Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. USA, 2003; 100:13225-30. https://doi.org/10.1073/pnas.1735528100.
Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev. Biochem. 2006; 75: 243-69. https://doi.org/10.1146/annurev.biochem.75.103004.142422.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006; 5: 769-84. https://doi.org/10.1038/nrd2133.
Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drigs, 2007; 16: 659-78. https://doi.org/10.1517/135437188.8.131.529.
Simonini, MV et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. USA, 2006; 103: 1587-92. https://doi.org/10.1073/pnas.0510341103.
Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodeling. Nature, 2007; 447: 178-82. https://doi.org/10.1038/nature05772.
Tao R et al. Deacetylase inhibition promotes the generations and function of regulatory T cells. Nat. Med. 2007; 13: 1299-307. https://doi.org/10.1038/nm1652.
Johnson J, Pahuja A, Graham M, Hering B, Hancock W W, Bansal-Pakala P. Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. Transpl. Proc. 2008; 40: 459-61. https://doi.org/10.1016/j.transproceed.2008.01.039.
McGee SL, Hargreaves M. Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms. Clin. Exp. Pharmacol. Physiol. 2008; 33: 395-99. https://doi.org/10.1111/j.1440-1681.2006.04362.x.
Lee MG et al. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 2006; 13: 563-67. https://doi.org/10.1016/j.chembiol.2006.05.004.
Razin A, Riggs AD. DNA methylation and gene function. Science, 1980; 210: 604-10. https://doi.org/10.1126/science.6254144.
Razin A, Cedar H. Distribution of 5-methylcytosine in chromatin. Proc. Natl. Acad. Sci. USA 1977; 74: 2725-28. https://doi.org/10.1073/pnas.74.7.2725.
D’Alessio AC, Szyf M. Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem. Cell Biol. 2006; 84: 463-76. https://doi.org/10.1139/o06-090.
Weaver, ICG et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004; 7:847-54. https://doi.org/10.1038/nn1276.
Weidner CI, Lin Q, Koch CM, Eisele L, Beier F, Ziegler P, Bauerschlag DO, Jöckel KH, Erbel R, Mühleisen TW, Zenke M, Brümmendorf TH, Wagner W. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014; 15(2): R24. https://doi.org/10.1186/gb-2014-15-2-r24.
Copyright (c) 2020 PAJAR - Pan American Journal of Aging Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
The submission of originals to PAJAR implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite PAJAR as the site of original publication.
Creative Commons License
Except where otherwise specified, material published in this journal is licensed under a Creative Commons Attribution 4.0 International license, which allows unrestricted use, distribution and reproduction in any medium, provided the original publication is correctly cited.